Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AKST4290 in Parkinson's disease on stable dopaminergic treatment
2019-001657-42Phase 2Completed
- Sponsor
- Alkahest, Inc.
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing AKST4290 with Placebo (2 arms). Primary endpoint: Change in motor function in off-medication state. Started Jun 2019; status: completed.
02
Drugs
BI 144807
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2019-001657-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001657-42.